Rethinking Tail Spend: Transforming Procurement Before Compliance Risks Escalate

In pharmaceutical and life sciences organisations, tail spend may represent a relatively small share of total expenditure, but it can create disproportionate compliance, operational and governance challenges. When non-strategic suppliers are managed outside standard procurement controls, organisations risk fragmented documentation, inconsistent supplier qualification and limited visibility across sites—issues that can become significant during audits, inspections and regulatory reviews.

Establishing a centralised system of record for tail spend helps procurement teams gain greater oversight of supplier activity, documentation and performance. With a clearer view of supplier relationships, organisations can identify duplication, improve standardisation, strengthen ESG reporting and uncover opportunities for cost optimisation. Combining AI-driven data analysis with procurement expertise further enhances this process, enabling faster identification of risks, supplier consolidation opportunities and compliance gaps while preserving the human judgement required in highly regulated environments. As regulatory scrutiny and supply chain complexity continue to increase, disciplined tail spend management is becoming a critical component of operational resilience and procurement governance.

Read the full article on Pharmaceutical Executive.